AzTrials
AzTrials

AdultFASTERNCT06916364

Utilization of Airway Stabilizing Rod to Assist With Laryngeal Mask Airway Guided Fiberoptic Intubation in Adults With Obesity

A study testing Fiberoptic Assisted Endotracheal Rod Intubation in people with Adult and Obesity, Morbid, run by Baylor College of Medicine at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record

Search all trials

Trial summary

The FASTER stabilizing rod offers the distinct advantage of intubating through the laryngeal mask airway with a fiberoptic scope via the FASTER stabilizing rod. The device allows for the provider to insert the endotracheal tube (ETT) with visual confirmation using the fiberoptic scope into the trachea. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Adult, Obesity, Morbid
What is being tested?
Fiberoptic Assisted Endotracheal Rod Intubation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
21 Apr 2025to 1 Sep 2025
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult (18-64 yrs),
  • Geriatric (65+ yrs)
  • BMI > 35 kg/m2
  • elective surgery requiring intubation

Who cannot join

  • pregnant woman
  • neonates
  • children
  • incarcerated patient
  • patient refusal

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Ben Taub General Hospital

    Houston, Texas, 77030

Other trials in United States

About this study

The FASTER stabilizing rod offers the distinct advantage of intubating through the laryngeal mask airway with a fiberoptic scope via the FASTER stabilizing rod. The device allows for the provider to insert the endotracheal tube (ETT) with visual confirmation using the fiberoptic scope into the trachea. The device then allows for the laryngeal mask airway to be removed while stabilizing the ETT to ensure the ETT does not get dislodged.

The purpose of this protocol is to clinically test the validated prototype that the investigators have built and previously tested in adults with obesity.

Read more

The primary aims are to evaluate 1) the time to intubation and 2) the number of intubation attempts. The secondary aim is to note any complications from time to intubation to PACU discharge.

These complications include: Hypoxemia (10% decrease from baseline for 45 seconds)1 Airway trauma (minor) Esophageal intubation Laryngospasm Bronchospasm Oro-pharyngeal bleeding Arrythmia Emesis Epistaxis Dental damage Post-operative sore throat Post-operative hoarseness Accidental extubation during removal of the LMA.

Read the detailed description

When a patient cannot be ventilated and/or intubated, the guidelines for airway management (ASA difficult airway algorithm) dictate that a laryngeal mask airway (LMA) be used as a rescue device to oxygenate and ventilate the patient. However, an LMA is generally temporary and ultimately needs to be replaced by an endotracheal tube (ETT).

At present, providers can use an exchange catheter through the LMA to place the ETT. However, all current techniques to place the ETT through the LMA are done WITHOUT direct visualization or the ability to provide oxygenation or ventilation. This has the possibility of either accidental tracheal extubation or esophageal intubation as well as the possibility of causing trauma to the airway, particularly of concern in a patient with a difficulty airway.

To bridge this gap, the investigators developed an innovative device called the FASTER that would allow for patients (children through adults) to have an ETT placed through the LMA under direct vision and while being able to oxygenate and ventilate, greatly improving safety.

The first step was to create a prototype that was validated in a mannequin (H-47253 ). Following this validation, the investigators created and successfully performed a feasibility study in children without difficult airway at Texas Children's demonstrating success and no adverse events (H-47253) . Following this feasibility study, and despite the FASTER device being completely external to the patient, given that the study was performed in children, the investigators obtained an IDE from the FDA for study in children specifically with difficulty airways. At present, the investigators have successfully completed an initial study in children (n=20) (H-50120) all with difficulty airways without any adverse events. In this study, children that were previously difficult to intubate having an average of three intubating attempts were intubated in a single attempt in an average of just 66 seconds.

The objective for this protocol is to demonstrate feasibility in using this device in adult obese patients. In this study, the investigators will be using this device that is completely external to the patient and only in adults (not including any protected classes of patients).

Moreover, in the completed study of children with actual difficulty airways, the investigators demonstrated tremendous success and patient benefit without any adverse events. In this protocol, the investigators will not enroll any patients with difficult airway nor any patients in protected classes.

Being tested
Fiberoptic Assisted Endotracheal Rod Intubation
Keywords
faster, Laryngeal mask airway guided intubation, Fiberoptic Intubation, Airway Stabilizing Rod
Medical subject headings
Obesity, Morbid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fiberoptic Assisted Endotracheal Rod IntubationDevice

    Also called FASTER

    Fiberoptic-Assisted Endotracheal Rod for Endotracheal Intubation Through a Supraglottic Airway

Study groups in NCT06916364
Study groupRoleWhat they receive
Morbid ObesityExperimentalElective surgery requiring intubation, Age > 18, BMI > 35 kg/m2
Receives: Device: Fiberoptic Assisted Endotracheal Rod Intubation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Intubation

    Time of disconnecting the circuit from supraglottic airway (SGA) to the presence of end tidal carbon dioxide (ETCO2) for intubation.

    Measured: 3 minutes

  2. Number of Intubation Attempts

    Defined as failure to capture end tidal carbon dioxide after completion of intubation.

    Measured: 5 minutes

Secondary outcomes (1)
  1. Complications

    These complications include number of participants with

    • Hypoxemia (10% decrease from baseline for 45 seconds)
    • Airway trauma (minor)
    • Esophageal intubation
    • Laryngospasm
    • Bronchospasm
    • Oro-pharyngeal bleeding
    • Arrhythmia
    • Emesis
    • Epistaxis
    • Dental damage
    • Post-operative sore throat
    • Post-operative hoarseness
    • Accidental extubation during removal of the LMA

    Measured: Up to 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2025
  2. Study start21 Apr 2025
  3. Primary completion31 Jul 2025 (estimated)
  4. Study completion1 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06916364
Sponsor's protocol ID
H-55523
Acronym
FASTER
Status last verified
May 2025
First submitted
25 Mar 2025
Last updated
14 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes

Publications

  • Kovatsis PG. Continuous ventilation during flexible fiberscopic-assisted intubation via supraglottic airways. Paediatr Anaesth. 2016 Apr;26(4):457-8. doi: 10.1111/pan.12863. No abstract available.

    PubMed 26956516
  • van Zundert TC, Wong DT, van Zundert AA. The LMA-Supreme as an intubation conduit in patients with known difficult airways: a prospective evaluation study. Acta Anaesthesiol Scand. 2013 Jan;57(1):77-81. doi: 10.1111/aas.12011. Epub 2012 Nov 21.

    PubMed 23167262
  • Apfelbaum JL, Hagberg CA, Connis RT, Abdelmalak BB, Agarkar M, Dutton RP, Fiadjoe JE, Greif R, Klock PA, Mercier D, Myatra SN, O'Sullivan EP, Rosenblatt WH, Sorbello M, Tung A. 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway. Anesthesiology. 2022 Jan 1;136(1):31-81. doi: 10.1097/ALN.0000000000004002.

    PubMed 34762729
  • Joffe AM, Aziz MF, Posner KL, Duggan LV, Mincer SL, Domino KB. Management of Difficult Tracheal Intubation: A Closed Claims Analysis. Anesthesiology. 2019 Oct;131(4):818-829. doi: 10.1097/ALN.0000000000002815.

    PubMed 31584884

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in